International CDKL5 Clinical Research Network

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-100
SponsorUniversity of Colorado, Denver

About this trial

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.

Eligibility criteria

Qualifiers

All children diagnosed with CDD age 1-month to 100 years of age that are receiving care at one of the study institutions or are registered with the International CDKL5 Disorder Database will be considered for the study population.

Disqualifiers

Individuals who do not meet study inclusion criteria.

Trial design

Treatments tested in this trial

  • No intervention.

Treatment groups

No treatment groups listed

Sponsors and collaborators

University of Colorado, Denver

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

National Institutes of Health (NIH)

Collaborator

International Foundation for CDKL5 Research

Collaborator